*VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA;
†Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy;
‡Interventional Cardiology Department, Hospital Italiano de Buenos Aires, Argentina;
§Department of Biostatistics, Virginia Commonwealth University, Richmond, VA;
¶Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy;
‖Mediterranea Cardiocentro, Napoli, Italy;
**Department of Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth University, Richmond, VA; and
††Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA.
Correspondence: Antonio Abbate, MD, PhD, VCU Pauley Heart Center, Virginia Commonwealth University, PO Box 980204, 1200 E Broad St, Richmond, VA 23298-0533 (e-mail: [email protected]).
The VCU-ART2 study was supported by an American Heart Association Scientist Development Grant 10SDG 3030051 and a Presidential Research Incentive Program of the Virginia Commonwealth University to A. Abbate and by an Institutional National Institute of Health K12 Award KL2RR031989 to B. W. Van Tassell. The VCU-ART3 study was supported by a grant from the National Institutes of Health (1R34HL121402-01) to A. Abbate and B. W. Van Tassell. Swedish Orphan Biovitrum provided anakinra and matching placebo for VCU-ART3.
A. Abbate and B. W. Van Tassell have served as consultants to Swedish Orphan Biovitrum LLC in the past. G. Biondi-Zoccai has consulted for Cardionovum, CrannMedical, InnovHeart, Meditrial, Opsens Medical, and Replycare. The remaining authors report no conflicts of interest.